Designed using a proprietary algorithm and optimised for specificity by stringent homology analysis, the set is the first set of its kind in the life sciences market
Qiagen has announced the delivery of the human druggable genome siRNA set to several pharmaceutical customers.
A powerful tool for drug discovery using RNAi, the set consists of 10,000 duplexes targeting 5000 specifically chosen druggable gene candidates.
Designed using a proprietary algorithm and optimised for specificity by stringent homology analysis, the human druggable genome siRNA set is the first set of its kind in the life sciences market.
"The field of RNAi has the potential to revolutionise future drug discovery, and chemically synthesised siRNA is the tool of choice for pharmaceutical and biotech companies who employ high-throughput RNAi screening approaches for target validation.
"We are very pleased with the interest that we have received from pharma and biotech companies since we introduced this new set" said Patrick Weiss, VP, gene silencing and RNA technologies, Qiagen.
One of Qiagen's first customers for the set is the Translational Genomics Research Institute (TGEN).
Spyro Mousses, director of Cancer Drug Development at the Institute, says: "New genome compatible tools and resources are required to fully utilise the power of RNAi for drug discovery.
"TGEN has pioneered new technologies for high throughput RNAi to enable truly functional genomics and chemogenomics, but application of these technologies for genome wide studies has been limited by the lack of very large-scale human siRNA libraries.
"The human druggable genome siRNA set represents an important milestone achievement in publicly available siRNA libraries".
The 10,000 duplexes in the set are fully annotated and all sequence information is disclosed.
Qiagen makes no claim to any discoveries made using this set, giving researchers complete freedom.
Purchase of the set confers a research use license from the Massachusetts Institute of Technology.
